Topical Collection

Poorly Soluble Drugs

Collection Editors:
Prof. Dr. Guy Van den Mooter
guy.vandenmooter@pharm.kuleuven.be

Prof. Dr. Holger Grohganz
holger.grohganz@sund.ku.dk

Prof. Dr. Korbinian Löbmann
korbinian.loebmann@sund.ku.dk

Prof. Dr. Thomas Rades
thomas.rades@sund.ku.dk

Message from the Collection Editors

Dear Colleagues,

Increasingly important bottlenecks for the development of medicines result from the poor aqueous solubilities and low dissolution rates of many small molecular weight drugs in the pipelines of pharmaceutical companies. To increase the solubilities and dissolution rates of drugs, and thus their bioavailabilities, several feasible approaches can be taken, and are of special interest, both in academia, and in the pharmaceutical industry. These include the conversion of crystalline drugs to their respective amorphous forms, the use of lipid based drug delivery systems, particle size reduction, salt-, co-crystal, and pro-drug formations, and the use of cyclodextrin complexes, to name but a few. This Special Issue aims to provide a forum for the dissemination of the latest information on new approaches and methods for dealing with poorly soluble drugs, and with methods of testing their success.

Prof. Dr. Korbinian Löbmann
Prof. Dr. Holger Grohganz
Prof. Dr. Guy Van den Mooter
Collection Editors

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 19 days after submission; acceptance to publication is undertaken in 6 days (median values for papers published in this journal in 2016).

Sections: published in twelve topical sections.